Clinical Trials Browser

Phase 2 × INDUSTRY × Deafness, Autosomal Recessive 39 × Clear all

NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Phase 2 Terminated

3 enrolled 6 charts

Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms